William Pao
Affiliations: | 2004-2009 | Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY, United States | |
| 2006-2009 | Weill Cornell Medical College, New York, NY, United States | ||
| 2009- | Vanderbilt University Medical School | ||
| 2014- | Roche Pharma |
Area:
Oncology, Molecular Biology, BiochemistryWebsite:
https://medicine.mc.vanderbilt.edu/hemonc_paoGoogle:
"William Pao"Bio:
https://www.roche.com/research_and_development/who_we_are_how_we_work/our_structure/pred/meet_our_leaders/meet_william_pao.htm
https://ch.linkedin.com/in/william-pao-40719295
https://books.google.com/books?id=5YcvAQAAIAAJ
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Adrian C. Hayday | grad student | 1990-1997 | Yale (Cell Biology Tree) | |
| (The development of murine dendritic epidermal T cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Obst-Sander U, Ricci A, Kuhn B, et al. (2022) Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of Medicinal Chemistry |
| Riely GJ, Lovly CM, Messina CG, et al. (2019) Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. Journal of Clinical Oncology. 37: 9062-9062 |
| Riely G, Lovly C, Messina C, et al. (2019) P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles Journal of Thoracic Oncology. 14 |
| Horn L, Gettinger S, Camidge DR, et al. (2017) Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer (Amsterdam, Netherlands). 113: 51-58 |
| Arbour KC, Kris MG, Riely GJ, et al. (2017) Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer |
| Ichihara E, Westover D, Meador CB, et al. (2017) SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Research |
| Hartmaier RJ, Charo J, Fabrizio D, et al. (2017) Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16 |
| Polosukhina D, Love HD, Correa H, et al. (2017) Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Molecular Oncology |
| Smit E, Soria J, Janjigian Y, et al. (2017) Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: The story so far Annals of Oncology. 28: ii30-ii31 |
| Yu HA, Sima C, Feldman D, et al. (2016) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology |